layer1-background

News

 
News
  Date Title View
Nov 9, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming Stifel 2016 Healthcare...
Nov 2, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ended September 30, 2016, and provided updates on its clinical developmen...
Oct 28, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that Willard Dere, M.D., Professor of Internal Medicine at the University of Utah Health Sciences Center and former Senior Vice President in Research and Development at Amgen, has been appointed to the...
Oct 24, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical data from STOP-ALF, a Phase 2a clinical trial to evaluate the Safety and Tolerability of Ornithine Phenylacetate (OCR-0...
Oct 10, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming 2016 BIO Investor Foru...
Sep 21, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced completion of enrollment in STOP-ALF,  a Phase 2a clinical trial to evaluate the Safety and Tolerability of Ornithine Phenylace...
Sep 20, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2nd...
Sep 19, 2016
--Phase 2b STOP-HE Enrollment Surpasses 205 Patients; On Track to Complete in Q4 2016-- PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic o...
Sep 15, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced a transition in the business development team at Ocera. Gaurav Aggarwal, M.D., Chief Business Officer of ...
Aug 3, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ended June 30, 2016, and provided updates on its clinical development pro...
1
...
NextLast
= add release to Briefcase